News - Ablynx

Filter

Current filters:

Ablynx

Popular Filters

Second research deal with Merck & Co for Ablynx

Second research deal with Merck & Co for Ablynx

03-02-2014

Belgian drugmaker Ablynx has entered into a second research collaboration and licensing agreement with…

AblynxLicensingMerck & CoOncologyPharmaceuticalResearch

Boehringer Ingelheim initiates Phase I study with Ablynx nanobody triggering milestone payment

Boehringer Ingelheim initiates Phase I study with Ablynx nanobody triggering milestone payment

29-10-2013

Ablynx says its partner Boehringer Ingelheim has dosed the first healthy volunteers in a Phase I clinical…

AblynxBoehringer IngelheimEuropeFinancialNanobodyNeurologicalPharmaceuticalResearch

Ablynx and Eddingpharm sign deal to target Chinese osteoporosis market

Ablynx and Eddingpharm sign deal to target Chinese osteoporosis market

18-10-2013

Ablynx has granted an exclusive license to Eddingpharm to develop and commercialize its anti-RANKL Nanobody,…

AblynxAsia-PacificEddingpharmLicensingPharmaceuticalWomen's Health

Ablynx to appoint three new directors and elect a new chairman of its board

Ablynx to appoint three new directors and elect a new chairman of its board

08-10-2013

Ablynx has announced that Peter Fellner, Bo Jesper Hansen and William Jenkins will be proposed for nomination…

AblynxBoardroomEurope

Ablynx and Merck Serono expand collaboration on Nanobodies

Ablynx and Merck Serono expand collaboration on Nanobodies

26-09-2013

Ablynx and Merck Serono have expanded their collaboration on the co-discovery and co-development of Nanobodies.

AblynxBiotechnologyEuropeImmunologicalsMerck SeronoNeurologicalOncologyResearch

Ablynx and AbbVie sign deal over rheumatoid arthritis nanobody

Ablynx and AbbVie sign deal over rheumatoid arthritis nanobody

23-09-2013

Belgian drug developer Ablynx and US drugmaker AbbVie have entered into a global license agreement to…

AbbVieAblynxAnti-Arthritics/RheumaticsEuropeLicensingPharmaceutical

Algeta and Ablynx collaborate on tumor-targeting Nanobodies

22-11-2012

Norway-based Algeta (OSE: ALGETA) and Belgian firm Ablynx (Euronext Brussels: ABLX) have entered a research…

AblynxAlgetaBiotechnologyLicensingNanobodiesNanobodyOncologyResearch

Ablynx extends Nanobody deal with Boehringer

21-03-2012

Belgian drug developer Ablynx (Euronext Brussels: ABLX) yesterday announced a two-year extension of the…

AblynxBiotechnologyBoehringer IngelheimImmunologicalsLicensingOncologyPharmaceuticalRespiratory and Pulmonary

Ablynx earns milestone from Merck Serono

13-12-2011

Belgium’s Ablynx (Euronext Brussels: ABLX) says it will earn a 1 million-euro ($1.3 million) from…

AblynxBiotechnologyFinancialImmunologicalsMerck KGaAMerck SeronoPharmaceuticalResearch

Merck Serono expands osteoarthritis collaboration with Ablynx

09-11-2011

Merck Serono, a division of Germany’s Merck KGaA (MRK: DE) has entered into a third agreement with…

AblynxAnti-Arthritics/RheumaticsLicensingMerck SeronoPharmaceuticalResearch

Pfizer returns rights to TNF-alpha targeting nanobodies to Ablynx

07-11-2011

Shares of Belgian drug developer Ablynx [Euronext Brussels: ABLX] fell 18.2% to 2.93 euros in morning…

AblynxAnti-Arthritics/RheumaticsLicensingozoralizumabPfizerPharmaceutical

Back to top